
Lindsay N Carpp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7340328/publications.pdf Version: 2024-02-01



Γινισέλν Ν ζάρορ

#	Article	lF	CITATIONS
1	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2022, 375, 43-50.	12.6	788
2	Orchestrating single-cell analysis with Bioconductor. Nature Methods, 2020, 17, 137-145.	19.0	488
3	A role for the actin cytoskeleton in cell death and aging in yeast. Journal of Cell Biology, 2004, 164, 803-809.	5.2	262
4	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2021, , eab3435.	12.6	145
5	The Sec1p/Munc18 protein Vps45p binds its cognate SNARE proteins via two distinct modes. Journal of Cell Biology, 2006, 173, 927-936.	5.2	96
6	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. Cell Host and Microbe, 2019, 26, 336-346.e3.	11.0	88
7	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Annals of Internal Medicine, 2021, 174, 221-228.	3.9	86
8	Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. Journal of Infectious Diseases, 2018, 217, 742-753.	4.0	80
9	Single-cell immunology of SARS-CoV-2 infection. Nature Biotechnology, 2022, 40, 30-41.	17.5	78
10	Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8378-E8387.	7.1	57
11	Homotypic Vacuole Fusion in Yeast Requires Organelle Acidification and Not the V-ATPase Membrane Domain. Developmental Cell, 2013, 27, 462-468.	7.0	52
12	Quantitative Proteomic Analysis of Host-virus Interactions Reveals a Role for Golgi Brefeldin A Resistance Factor 1 (GBF1) in Dengue Infection. Molecular and Cellular Proteomics, 2014, 13, 2836-2854.	3.8	49
13	Interaction between the yellow fever virus nonstructural protein NS3 and the host protein Alix contributes to the release of infectious particles. Microbes and Infection, 2011, 13, 85-95.	1.9	46
14	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Scientific Reports, 2021, 11, 23921.	3.3	44
15	A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine. Journal of Immunology, 2017, 199, 1476-1489.	0.8	40
16	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. Journal of Infectious Diseases, 2018, 217, 1280-1288.	4.0	32
17	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis, 2018, 109, 61-68.	1.9	28
18	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PLoS ONE, 2017, 12, e0185959.	2.5	27

LINDSAY N CARPP

#	Article	IF	CITATIONS
19	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. Journal of Virology, 2019, 93, .	3.4	26
20	Functional homology of mammalian syntaxin 16 and yeast Tlg2p reveals a conserved regulatory mechanism. Journal of Cell Science, 2009, 122, 2292-2299.	2.0	25
21	Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. PLoS Computational Biology, 2019, 15, e1006952.	3.2	25
22	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. Frontiers in Immunology, 2019, 10, 2741.	4.8	25
23	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. AIDS Research and Human Retroviruses, 2018, 34, 645-656.	1.1	23
24	HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. BMC Infectious Diseases, 2019, 19, 453.	2.9	23
25	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathogens, 2021, 17, e1009363.	4.7	19
26	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Human Vaccines and Immunotherapeutics, 2018, 14, 2116-2127.	3.3	17
27	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. PLoS ONE, 2020, 15, e0226803.	2.5	16
28	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Annals of Internal Medicine, 2021, 174, 1118-1125.	3.9	15
29	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine, 2021, 64, 103203.	6.1	14
30	The Sec1/Munc18 Protein Vps45 Regulates Cellular Levels of Its SNARE Binding Partners Tlg2 and Snc2 in Saccharomyces cerevisiae. PLoS ONE, 2012, 7, e49628.	2.5	13
31	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS ONE, 2017, 12, e0176428.	2.5	12
32	Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment. Viruses, 2019, 11, 607.	3.3	12
33	Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. Journal of Infectious Diseases, 2022, 226, 246-257.	4.0	11
34	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020—March 2021) Using a Statistical Learning Strategy. Viruses, 2022, 14, 9.	3.3	10
35	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. PLoS ONE, 2020, 15, e0234236.	2.5	9
36	Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. American Journal of Tropical Medicine and Hygiene, 2019, 101, 164-179.	1.4	9

LINDSAY N CARPP

#	Article	IF	CITATIONS
37	Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. Frontiers in Big Data, 2021, 4, 672460.	2.9	8
38	Cellular levels of the syntaxin Tlg2p are regulated by a single mode of binding to Vps45p. Biochemical and Biophysical Research Communications, 2007, 363, 857-860.	2.1	7
39	Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10.	3.3	6
40	Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case–control study. ELife, 2022, 11, .	6.0	4
41	Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 434-439.	2.1	3
42	Early Pro-Inflammatory Signal and T-Cell Activation Associate With Vaccine-Induced Anti-Vaccinia Protective Neutralizing Antibodies. Frontiers in Immunology, 2021, 12, 737487.	4.8	2
43	Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials. Journal of Infectious Diseases, 2022, 225, 332-340.	4.0	1
44	Title is missing!. , 2020, 15, e0234236.		0
45	Title is missing!. , 2020, 15, e0234236.		0
46	Title is missing!. , 2020, 15, e0234236.		0
47	Title is missing!. , 2020, 15, e0234236.		0